Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ⅰ/Ⅱ Study of TTI-622 in Combination With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer

NCT05261490 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05261490
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05261490 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ⅰ/Ⅱ Study of TTI-622 in Combination With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer
Lead sponsor
Pfizer
Phase
Phase 1/2
Overall status
Terminated
Start date
August 1, 2022
Completion date
February 15, 2024
Enrollment
10 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

epithelial ovarian cancer, fallopian tube cancer, ovarian cancer, ovarian carcinoma, ovarian neoplasms, primary peritoneal carcinoma